These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 17990141)
1. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Rüfer A; Brodmann D; Gregor M; Kremer Hovinga JA; Lämmle B; Wuillemin WA Swiss Med Wkly; 2007 Sep; 137(37-38):518-24. PubMed ID: 17990141 [TBL] [Abstract][Full Text] [Related]
2. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Scully M; Cohen H; Cavenagh J; Benjamin S; Starke R; Killick S; Mackie I; Machin SJ Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847 [TBL] [Abstract][Full Text] [Related]
3. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904 [TBL] [Abstract][Full Text] [Related]
4. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Elliott MA; Heit JA; Pruthi RK; Gastineau DA; Winters JL; Hook CC Eur J Haematol; 2009 Oct; 83(4):365-72. PubMed ID: 19508684 [TBL] [Abstract][Full Text] [Related]
5. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Caramazza D; Quintini G; Abbene I; Malato A; Saccullo G; Lo Coco L; Di Trapani R; Palazzolo R; Barone R; Mazzola G; Rizzo S; Ragonese P; Aridon P; Abbadessa V; Siragusa S Transfusion; 2010 Dec; 50(12):2753-60. PubMed ID: 20576013 [TBL] [Abstract][Full Text] [Related]
6. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Fakhouri F; Vernant JP; Veyradier A; Wolf M; Kaplanski G; Binaut R; Rieger M; Scheiflinger F; Poullin P; Deroure B; Delarue R; Lesavre P; Vanhille P; Hermine O; Remuzzi G; Grünfeld JP Blood; 2005 Sep; 106(6):1932-7. PubMed ID: 15933059 [TBL] [Abstract][Full Text] [Related]
7. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Sadler JE Blood; 2008 Jul; 112(1):11-8. PubMed ID: 18574040 [TBL] [Abstract][Full Text] [Related]
8. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Yomtovian R; Niklinski W; Silver B; Sarode R; Tsai HM Br J Haematol; 2004 Mar; 124(6):787-95. PubMed ID: 15009067 [TBL] [Abstract][Full Text] [Related]
9. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Zheng X; Pallera AM; Goodnough LT; Sadler JE; Blinder MA Ann Intern Med; 2003 Jan; 138(2):105-8. PubMed ID: 12529092 [TBL] [Abstract][Full Text] [Related]
10. Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review. Harambat J; Lamireau D; Delmas Y; Ryman A; Llanas B; Brissaud O Pediatr Crit Care Med; 2011 Mar; 12(2):e90-3. PubMed ID: 20625343 [TBL] [Abstract][Full Text] [Related]
11. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Böhm M; Betz C; Miesbach W; Krause M; von Auer C; Geiger H; Scharrer I Br J Haematol; 2005 Jun; 129(5):644-52. PubMed ID: 15916687 [TBL] [Abstract][Full Text] [Related]
12. Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab. Hagel S; Jantsch J; Budde U; Kalden JR; Eckardt KU; Veelken R Thromb Haemost; 2008 Jul; 100(1):151-3. PubMed ID: 18612551 [No Abstract] [Full Text] [Related]
13. [Rituximab provided long-term remission in a patient with severe thrombotic thrombocytopenic purpura refractory to plasma exchange]. Hong H; Aoyama Y; Yamamura R; Ohta T; Mugitani A; Yamane T; Hino M; Matsumoto M; Fujimura Y Rinsho Ketsueki; 2006 Dec; 47(12):1528-32. PubMed ID: 17233471 [TBL] [Abstract][Full Text] [Related]
14. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Ling HT; Field JJ; Blinder MA Am J Hematol; 2009 Jul; 84(7):418-21. PubMed ID: 19507208 [TBL] [Abstract][Full Text] [Related]
15. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Foley SR; Webert K; Arnold DM; Rock GA; Clark WF; Barth D; Sutton DM; Kidney Int Suppl; 2009 Feb; (112):S55-8. PubMed ID: 19180138 [TBL] [Abstract][Full Text] [Related]
16. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Bresin E; Gastoldi S; Daina E; Belotti D; Pogliani E; Perseghin P; Scalzulli PR; Paolini R; Marcenò R; Remuzzi G; Galbusera M Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804 [TBL] [Abstract][Full Text] [Related]
17. Current insight into thrombotic thrombocytopenic purpura. Verbeke L; Delforge M; Dierickx D Blood Coagul Fibrinolysis; 2010 Jan; 21(1):3-10. PubMed ID: 19851089 [TBL] [Abstract][Full Text] [Related]
18. [Successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura refractory to plasma exchange]. Koshino M; Kudou D; Okoshi Y; Obara N; Simizu S; Mukai HY; Suzukawa K; Hasegawa Y; Kojima H; Nagasawa T; Chiba S Rinsho Ketsueki; 2010 Feb; 51(2):127-31. PubMed ID: 20379104 [TBL] [Abstract][Full Text] [Related]
19. Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab. Goyal J; Adamski J; Lima JL; Marques MB J Clin Apher; 2013 Dec; 28(6):390-4. PubMed ID: 23857472 [TBL] [Abstract][Full Text] [Related]
20. Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. van Balen T; Schreuder MF; de Jong H; van de Kar NC Eur J Haematol; 2014 Jan; 92(1):80-2. PubMed ID: 24118335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]